Castle Biosciences, Inc.
CSTL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.28 | 0.02 | 0.06 | -1.17 |
| FCF Yield | 1.96% | -1.88% | 2.24% | 2.14% |
| EV / EBITDA | -128.33 | 144.99 | 47.74 | 60.36 |
| Quality | ||||
| ROIC | 27.03% | -5.87% | 1.02% | 0.29% |
| Gross Margin | 76.64% | 81.38% | 81.25% | 81.80% |
| Cash Conversion Ratio | -45.17 | 4.60 | 0.23 | 2.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 21.40% | 27.38% | 31.62% | 34.32% |
| Free Cash Flow Growth | 207.26% | -164.15% | -0.96% | -9.64% |
| Safety | ||||
| Net Debt / EBITDA | 10.56 | -18.19 | -6.79 | -5.67 |
| Interest Coverage | -202.43 | -1,642.82 | 44.02 | 25.27 |
| Efficiency | ||||
| Inventory Turnover | 2.41 | 2.39 | 1.99 | 2.38 |
| Cash Conversion Cycle | 33.10 | 48.56 | 60.27 | 51.36 |